Abstract:Background Polygenic risk scores (PRS) have ushered in a new era in genetic epidemiology, offering insights into individual predispositions to a wide range of diseases. However, despite recent marked enhancements in their predictive power, there are still challenges that need to be overcome before PRS-based models can be broadly applied in the clinic, including sufficient accuracy, easy interpretability and portability across diverse populations. Methods Leveraging trans-ancestry genome-wide association study (GWAS) meta-analysis, we generated novel, diverse summary statistics for 30 medically-related traits which were used to benchmark the performance of six existing PRS algorithms using UK biobank. Observing that SBayesRC had the best overall performance but recognizing strengths in each method, we developed an ensemble PRS model using logistic regression to combine outputs from top-performing algorithms. This ensemble model was validated on the diverse eMERGE and PAGE MEC cohorts, and the performance was compared against current state-of-the-art PRS models. To enhance predictive accuracy for clinical application, we incorporated easily-accessible clinical characteristics such as age, gender, ancestry and risk factors, creating disease prediction models intended as prospective diagnostic tests, with easily interpretable positive or negative outcomes. Results Predictive performance of PRS models improved with trans-ancestry GWAS meta-analysis and was further enhanced by the ensemble model, which surpassed state-of-art PRS models. When applied to external cohorts, performance drops were minimal, indicating good calibration. After adding clinical characteristics, 12 out of 30 models surpassed 80% AUC. Further, 25 traits exceeded the diagnostic odds ratio (DOR) of 5 and 19 traits exceeded DOR of 10 for all ancestry groups, indicating high predictive value. The highest DOR in a population with a sufficient number of cases was 66.2 for Alzheimer's disease in Europeans. Our PRS model for coronary artery disease identified 55-80 times more true coronary events than rare pathogenic variant models, reinforcing its clinical potential. The polygenic component modulated the effect of high-risk rare variants, stressing the need to consider all genetic components in clinical settings. Conclusions Newly developed PRS-based disease prediction models have sufficient accuracy and portability to warrant consideration of being used in the clinic.

Integration of Rare Large-Effect Expression Variants Improves Polygenic Risk Prediction

Integration of Rare Expression Outlier-Associated Variants Improves Polygenic Risk Prediction.

Integrating Common and Rare Variants Improves Polygenic Risk Prediction Across Diverse Populations

Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data

Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Significant sparse polygenic risk scores across 813 traits in UK Biobank

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models

Polygenic risk and rare variant gene clustering enhance cancer risk stratification for breast and prostate cancers

Rare variant effect estimation and polygenic risk prediction

All of Us diversity and scale improve polygenic prediction contextually with greatest improvements for under-represented populations

Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification

A comprehensive investigation of statistical and machine learning approaches for predicting complex human diseases on genomic variants

How to improve polygenic prediction from whole-genome sequencing data by leveraging predicted epigenomic features?

Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction

Leveraging Effect Size Distributions to Improve Polygenic Risk Scores Derived from Summary Statistics of Genome-Wide Association Studies.

Polygenic risk scores: from research tools to clinical instruments

Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations

Clinical use of current polygenic risk scores may exacerbate health disparities

Genomic Prediction of Complex Disease Risk